Source: ERJ Open Res, 6 (2) 00174-2019; 10.1183/23120541.00174-2019
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
Clémence Legoupil, Didier Debieuvre, Aurelien Marabelle, Stefan Michiels, Raïssa Kapso, Benjamin Besse, Julia Bonastre. A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. ERJ Open Res, 6 (2) 00174-2019; 10.1183/23120541.00174-2019

Member's Comments

No comment yet.

Related content which might interest you: A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 Utilisation of biomarker testing to guide therapy in non-small cell lung cancer in a regional lung cancer service Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019 Year: 2020 Assessing the relevance of biological prognostic indices in predicting survival in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)? Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 Identification of predictive biomarkers of immunotherapy response in non-small cell lung cancer by multiparametric analysis Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer Source: Eur Respir J 2006; 27: 895-901 Year: 2006 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Lung function and quality of life after surgical treatment of non-small cell lung cancer – preliminary results Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008 Effect of comorbidity on the prognosis of non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006 Chemotherapy improves low performance status lung cancer patients Source: Eur Respir J 2007; 30: 1186-1192 Year: 2007